Gilead Sciences, Inc. (GILD)
Pre-market:
| Previous close | 64.70 |
| Open | 64.54 |
| Bid | 65.19 x 200 |
| Ask | 65.25 x 400 |
| Day's range | 64.04 - 65.28 |
| 52-week range | 62.07 - 87.87 |
| Volume | |
| Avg. volume | 7,063,617 |
| Market cap | 81.292B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 181.25 |
| EPS (TTM) | 0.36 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.08 (4.72%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | 81.21 |
ZacksGilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
